SynthesisAllergy2025
Systematic Review and Meta-Analysis of Oral Immunotherapy Effect on Food Allergy-Related Quality of Life.
Synthesis in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Living with Food Allergy in Adolescence: The Nutritional and Psychological Impact of Allergen Avoidance.Nutrients · 2025Review
- Considerations for biologics as front-line treatment in allergic diseases.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUncertainty exists regarding the health-related quality of life (HRQL) benefits of food allergen oral immunotherapy (OIT). Up-to-date meta-analyses incorporating HRQL data from recent randomised trials are lacking.
methodsSystematic searches of MEDLINE, Embase, CENTRAL and Google Scholar were conducted for food OIT randomised trials (versus any comparator) that measured HRQL with a validated instrument (27 July 2023). Hedges' g standardised mean differences in HRQL between OIT and comparator were analysed by allergen, reporting perspective, and treatment/post-treatment periods, and synthesised using random-effects meta-analysis models when results from multiple trials were available.
resultsTen trials (nine peanut, one baked milk; N = 1330) were included. No between-group differences were observed in parent-reported child HRQL (g = -0.07, 95% CI: -0.19 to 0.04, 9 trials, N = 1259), self-reported child HRQL (g = -0.23, 95% CI: -0.73 to 0.27, 5 trials, N = 435), or self-reported teenager HRQL (g = 0.00, 95% CI: -0.41 to 0.40, 3 trials, N = 209) during peanut OIT treatment. However, 12 months post-treatment, improved parent-reported child HRQL was observed (g = -0.51, 95% CI: -0.84 to -0.19, 3 comparisons from 2 trials, N = 213). No between-group differences were observed in the baked milk OIT trial in children (g = 0.118, 95% CI: -0.63 to 0.87, N = 26).
conclusionHRQL benefits were observed after OIT protocol completion, with limited evidence of benefit during active treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.